| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1033113102 |
| P356 | DOI | 10.1016/J.CLPT.2004.04.003 |
| P698 | PubMed publication ID | 15289794 |
| P50 | author | Mirko Faber | Q37367744 |
| P2093 | author name string | Uwe Fuhr | |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 178-184 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Time response of cytochrome P450 1A2 activity on cessation of heavy smoking | |
| P478 | volume | 76 |
| Q42906463 | A Mechanism-Based Mathematical Model of Aryl Hydrocarbon Receptor-Mediated CYP1A Induction in Rats Using β-Naphthoflavone as a Tool Compound |
| Q34052455 | A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities |
| Q36720920 | Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach |
| Q53559897 | Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study i |
| Q36485692 | CYP induction-mediated drug interactions: in vitro assessment and clinical implications |
| Q57398058 | Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension |
| Q44893470 | Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method |
| Q45226003 | Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study |
| Q38099541 | Cigarette smoking and clopidogrel interaction |
| Q41874943 | Cigarette smoking might weaken the prognostic significance of cytochrome P450 2C19*2 polymorphism in acute myocardial infarction patients |
| Q40192653 | Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes |
| Q54330729 | Does dioxin exert toxic effects in humans at or near current background body levels?: An evidence-based conclusion. |
| Q28247018 | Drug interactions with smoking |
| Q34432843 | Drug-drug interactions between warfarin and psychotropics: updated review of the literature |
| Q55020795 | Effects of Switching to the Tobacco Heating System 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings ( |
| Q46936376 | Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine |
| Q34303604 | Effects of tobacco smoking and nicotine on cancer treatment |
| Q50277300 | Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland |
| Q63241939 | Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy |
| Q37631543 | Factors affecting the development of adverse drug reactions (Review article) |
| Q57550190 | Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility |
| Q54414633 | Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease. |
| Q37710240 | Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment |
| Q37724295 | In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation |
| Q46433552 | Influence of cigarette smoking on melatonin levels in man. |
| Q51498312 | Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. |
| Q37176153 | Interaction between cigarette smoking and clinical benefit of clopidogrel |
| Q48170893 | Letter in Reply to Arno et al. "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". |
| Q36985086 | Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment |
| Q40306549 | Mechanisms and Consequences of Drug-Drug Interactions |
| Q50798789 | Methadone toxicity due to smoking cessation--a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. |
| Q64248828 | Noninvasive Evaluation of Liver Function in Morbidly Obese Patients |
| Q53097229 | Patient case: impact of smoking cessation on international normalized ratio. |
| Q36054907 | PharmGKB summary: caffeine pathway |
| Q36110592 | Pharmacogenetics of analgesic drugs |
| Q38815352 | Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products |
| Q34139392 | Pharmacokinetics and Metabolism of Natural Methylxanthines in Animal and Man |
| Q37514319 | Pharmacokinetics and drug metabolism in the elderly |
| Q37678656 | Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions |
| Q33571417 | Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia |
| Q47752166 | Predicting drug interactions in addiction treatment. |
| Q101403207 | Reduced levels of biomarkers of exposure in smokers switching to the Carbon-Heated Tobacco Product 1.0: a controlled, randomized, open-label 5-day exposure trial |
| Q36522045 | Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents |
| Q38290164 | Smoking and mental illness. An update for psychiatrists |
| Q37159031 | Smoking and opioid detoxification: behavioral changes and response to treatment. |
| Q42756776 | Smoking cessation and neuropsychiatric adverse events: are family physicians caught between a rock and a hard place? |
| Q43061630 | Smoking cessation through the utilization of pharmacotherapy. |
| Q35015993 | Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. |
| Q38972963 | The challenge of reducing smoking in people with serious mental illness |
| Q37106069 | The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo |
| Q36582619 | Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance |
| Q36844830 | Tobacco smoking within psychiatric inpatient settings: biopsychosocial perspective |
| Q37362600 | Treating patients with respiratory disease who smoke |
| Q46129161 | Abandon du tabagisme et effets neuropsychiatriques indésirables: Les médecins de famille sont-ils coincés entre l’arbre et l’écorce? |
Search more.